AI summary by TwinMind

The Curious Case of the Disappearing Polymorph

Asianometry

17m 18s

FDA Approval and Initial Production (1996-1998)

  • Early 1996: FDA approved revolutionary HIV drug ritonavir (Norvir)
  • Abbott Labs began immediate production for tens of thousands of HIV patients
  • 240 lots of drug tablets produced without incident
  • Early 1998: New drug form spontaneously appeared, rapidly spread through entire factory
  • Production halted completely

Drug Polymorphism Background

  • Active pharmaceutical ingredients exist in multiple solid forms
    • Amorphous: molecules jumbled without defined shape
    • Crystalline: molecules arranged in orderly lattice
  • Polymorphism discovered 1821 by German chemist Eilhard Mitscherlich
    • Same chemical composition, different physical properties
    • Examples: aragonite vs calcite (both calcium carbonate), glycine amino acid
  • Polymorphs affect: texture, shelf life, room temperature stability, light/air exposure
  • Polymorphs can transform under right conditions
  • Aspirin example: Form 2 discovered 2004 via computer simulation, confirmed 2005

HIV Treatment Evolution

  • HIV leads to AIDS if untreated
  • First drugs: nucleoside analog reverse transcriptase inhibitors (NRTIs)
    • AZT most famous
    • Virus eventually develops resistance
  • 1995: New class emerged - protease inhibitors
    • Different mechanism: blocks HIV protease enzyme
    • Prevents viral reproduction by stopping protein chain chopping
    • Significant breakthrough in HIV treatment

Ritonavir Development

  • 1982: Abbott noticed HIV protease resembled renin enzyme (blood pressure research)
  • Scientists re-engineered renin work to block HIV protease
  • Computer-assisted design generated hundreds of candidates
  • 1992: Three candidates chosen, two failed
  • ABT-538 (ritonavir) showed instant results
  • December 1995: Human study showed significant viral load reduction
    • White blood cell counts nearly doubled
    • Side effects: diarrhea, nausea, headaches
  • March 1996: FDA advisory panel recommended approval
  • January 1996: Abbott began production before approval
  • Demand incredible: Canadians traveled to US, 224 bottles stolen from Canadian offices
  • Combined with other drugs for highly active anti-retroviral therapy (HAART)

The Crisis Emerges (Early 1998)

  • 2 years into market entry: Chicago factory noticed problems
  • Ritonavir sold in two formulations: liquid and semi-solid capsule
  • Capsule form: drug dissolved in semi-solid wax substance
  • Early 1998: Capsules started failing dissolution tests
  • Drug precipitating out of capsules, separating into solid crystals
  • Microscope examination: Expected rod/rectangular crystals, found fine needle clusters
  • X-ray powder diffraction confirmed new polymorph: Form 2

Form 2 Characteristics

  • More thermodynamically stable than Form 1
  • All hydrogen bonds satisfied
  • 5 times less soluble in ethanol-water solutions
  • Form 1 manufacturing process incompatible with Form 2
  • Extremely contagious: 1 part per million can convert entire batch
  • Form 2 took over Chicago factory's entire output
  • Scientists traveled Chicago to Italy factory to investigate
  • Italian factory's ritonavir converted to Form 2 after visit

Supply Crisis and Patient Impact

  • July 1998: Drugstores running through existing capsule supplies
  • Abbott held regular press conferences
  • Quote: "No gradual trend, something occurred that caused new form... no early warning, didn't know how to detect, test for, prevent, or clean it"
  • 70,000 patients relying on drug for cocktails
  • Abbott provided liquid formulation as substitute
  • Liquid version worked but tasted extremely bad ("vile")
  • Patient quote: "Like awful liquor that makes mouth and gut tingle and sting"
  • Suggested mixers: chocolate milk, Ensure, granola bars, toast with peanut butter, Nutella
  • Additional concerns: 43% alcohol content, storage requirements in warmer temperatures

Abbott's Response Efforts

  • Hundreds of scientists assigned dual approach:
    1. Solid formulation for Form 2 variant
    2. New pathway to consistently produce Form 1
  • Extensive efforts to restore Form 1 production:
    • Countless experiments
    • Reconditioned facilities
    • Rebuilt facilities and new lines
    • Visited organizations worldwide for clean environments
    • Every location contaminated with Form 2 within 5-6 weeks
  • Dr. Eugene Sun declared: "Never be able to go back to Form 1"
  • Form 1 capsules would be "gone supposedly for good"

Resolution and New Formulation

  • Prior to crisis: Abbott developing soft gelatin capsule
  • March 1999: Began FDA approval process for gel capsule with Form 2
  • July 1999: FDA approved new gelatin capsule format
  • Crisis officially ended
  • Financial impact: $250 million potential revenue lost
  • Cost: hundreds of employees worked 24/7, gave up summers/vacations

Later Discoveries

  • Scientists later found ways to convert Form 2 back to Form 1 (time-consuming, careful effort)
  • 2010: Hot melt extrusion method discovered for Form 1 capsules
  • Total of 5 forms discovered:
    • Form 3: emerges when exposed to liquid solvent
    • Form 5: Form 3 exposed to water
    • Form 5 can convert to Form 1

Origin Theory

  • Form 2 source unclear
  • Abbott's conclusion: manufactured Form 1 lot had liquid solvent dry up in manufacturing cycle
  • Created residue that crystallized into Form 2, contaminating equipment
  • Later paper suggested mechanical milling action (with/without liquid) can cause Form 1 to transition to Form 2 seeds
  • Molecule size and complexity likely why Form 2 not discovered initially

Industry Impact

  • 2008: Similar crisis with Parkinson's drug rotigotine (Neupro patch)
  • New crystal polymorph crystallized on patches, reducing effectiveness
  • Product withdrawn and reworked
  • Ongoing concern for pharmaceutical manufacturing ramp-up
  • Comparison to Kurt Vonnegut's "Cat's Cradle" Ice-nine concept

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome